Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Apr;36(2):115-20.
doi: 10.4143/crt.2004.36.2.115. Epub 2004 Apr 30.

Oxaliplatin with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (Modified FOLFOX 4) as first-line therapy for patients with metastatic colorectal cancer

Hyuk-Chan Kwon  1 , Kyoung Tae Kim, Shin Ae Lee, Jong-Sung Park, Sung-Hyun Kim, Jae-Seok Kim, Hyo Jin Kim
Affiliations

Oxaliplatin with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (Modified FOLFOX 4) as first-line therapy for patients with metastatic colorectal cancer

Hyuk-Chan Kwon et al. Cancer Res Treat. 2004 Apr.

Abstract

Purpose: To determine the activity and toxicities of low dose leucovorin (LV) plus fluorouracil (5-FU) regimen, combined with oxaliplatin every two weeks (modified FOLFOX 4), as a first-line therapy for patients with metastatic colorectal cancer.

Materials and methods: Between March 2001 and August 2003, fifty-five patients were enrolled in this study. Patients were treated with oxaliplatin 85 mg/m(2) as a 2-hour infusion at days 1 plus LV 20 mg/m(2) over 10 minutes, followed by 5-FU bolusa 400 mg/m(2) bolus and 22 hour continuous infusion of 600 mg/m(2) 5-FU at day 1 approximately 2. This treatment was repeated in 2 week intervals.

Results: The objective response rate was 40% on an intent-to-treatment analysis. Three patients (6%) demonstrated a complete response and nineteen patients (38%) showed a partial response. Sixteen patients (32%) showed a stable disease and eleven patients (22%) progressed during the course of the treatment. The median time to progression and overall survival time were as 6.6 months (95% CI: 4.98 approximately 8.02 months) and the median overall survival time was 17.0 months (95% CI: 9.15 approximately 24.85 months) from the start of the chemotherapy, respectively. A total of 275 cycles were analyzed for toxicity. Major hematologic toxicities included grade 1 approximately 2 anemia (23.5%), neutropenia (25.3%) and thrombocytopenia (10.6%). There were only 2 cycles of neutropenic fever. The most common non-hematologic toxicities were grade 1 approximately 2 nausea/vomiting (10.9%), diarrhea (9.1%) and grade 1 neuropathy (18.0%). There was no treatment related death.

Conclusion: The modified folfox 4 regimen is safe and effective regimen as a first-line therapy in advanced colorectal cancer patients.

Keywords: 5-FU; Chemotherapy; Colorectal neoplasm; Leucovorin; Oxaliplatin.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Kaplan-Meier probability of time to progression (TTP) and overall survival (OS).
See this image and copyright information in PMC

Comment in

References

    1. Shin HR, Ahn YO, Bae JM, Shin MH, Lee DH, Lee CW, Ohrr H, Ahn DH, Ferlay J, Parkin DM, Oh DK, Park JG, Bae JM, Won YJ, Jung KW, Park JG. Cancer incidence in Korea. Cancer Res Treat. 2002;34:405–408. - PubMed
    1. American Cancer Society: Cancer Facts and Figures-2000. Atlanta, GA: American Cancer Society; 2000.
    1. Jonker DJ, Maroun JA, Kocha W. Survival benefit of chemotherapy in metastatic colorectal cancer: A meta-analysis of randomised controlled trials. Br J Cancer. 2000;82:1789–1794. - PMC - PubMed
    1. Water J, Cunningham D. The changing face of chemotherapy in colorectal cancer. Br J Cancer. 2001;84:1–7. - PMC - PubMed
    1. Raymond E, Buquet-Fagot C, Djelloul S, Mester J, Cvitkovic E, Allain P, Louvet C, Gespach C. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast, and ovarian cancers. Anticancer Drugs. 1997;8:876–885. - PubMed

LinkOut - more resources